Loading
Ovarian Function and Disorders · Journal article
Journal of Ovarian Research · September 9, 2026
Raises a question worth testing. It does not answer one.
This retrospective cross-sectional study reports that the MTHFR C677T TT genotype is associated with elevated homocysteine (HCY) levels and a trend toward adverse metabolic markers in 213 women with polyendocrine metabolic ovarian syndrome (PMOS). Pathway analyses suggested a statistical relationship among genotype, HCY, and insulin resistance, but the authors explicitly acknowledge that the cross-sectional design precludes causal interpretation and call the metabolic implications exploratory, requiring prospective multicenter validation.
Retrospective cross-sectional genotyping study. Women diagnosed with PMOS at the Reproductive Medicine Center, General Hospital of Ningxia Medical University; eligibility criteria not specified in source.. n = 213. Reproductive Medicine Center, General Hospital of Ningxia Medical University (single centre in Ningxia, China implied)..
HCY levels differed significantly among the three genotype groups (CC, CT, TT). The TT group had the highest HCY levels, with this pattern consistent across BMI strata. The TT group showed a tendency toward a more adverse metabolic profile with relatively higher lipid-related and inflammatory indicators.
The TT group showed a tendency toward a more adverse metabolic profile with relatively higher lipid-related and inflammatory indicators.
These findings are too preliminary to guide clinical practice. The mechanistic hypothesis requires prospective validation; no recommendation for MTHFR genotyping or HCY measurement in PMOS management can be drawn from this descriptive cross-sectional analysis.
A retrospective, cross-sectional genotyping study proposing a mechanistic pathway (MTHFR genotype → homocysteine → metabolic heterogeneity) without causal evidence; the authors acknowledge exploratory design and explicitly call for prospective validation.
As stated by the source record.
Quoted from the source exactly as published.
These findings are too preliminary to guide clinical practice. The mechanistic hypothesis requires prospective validation; no recommendation for MTHFR genotyping or HCY measurement in PMOS management can be drawn from this descriptive cross-sectional analysis.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is characterized by diverse endocrine and metabolic abnormalities. Patients differ substantially in obesity, insulin resistance, and cardiometabolic risk. Homocysteine (HCY) is associated with insulin resistance and metabolic abnormalities in patients with PMOS, and the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is an important genetic factor that influences HCY levels. However, whether MTHFR C677T genotype-associated HCY elevation is related to metabolic heterogeneity within PMOS remains unclear. A total of 213 women diagnosed with PMOS at the Reproductive Medicine Center, General Hospital of Ningxia Medical University, were retrospectively analyzed. Based on MTHFR C677T genotyping results, the participants were classified as the homozygous wild-type genotype C/C (CC, n = 48), the heterozygous genotype C/T (CT, n = 124), or the homozygous variant genotype T/T (TT, n = 41). Differences in clinical characteristics, glucose and lipid metabolism indices, inflammatory markers, and reproductive hormone levels were compared among the groups. Multivariable regression was used to evaluate the primary genotype-HCY association, whereas correlation, pathway, and prediction analyses were considered exploratory. HCY levels differed significantly among the genotypes. The TT group had the highest HCY levels, and this pattern remained consistent across BMI strata. The TT group also showed a tendency toward a more adverse metabolic profile, with relatively higher lipid-related and inflammatory indicators. Exploratory genotype-stratified analyses suggested that, within the TT group, higher HCY was associated with a less favorable metabolic pattern, particularly higher triglyceride levels. Pathway analysis further suggested a statistical relationship among MTHFR C677T genotype, HCY, and insulin resistance, although the cross-sectional design precluded causal interpretation. Prediction analyses also indicated that HCY contributed to the identification of the TT-associated high-HCY phenotype. These exploratory findings are presented in the Supplementary Material and require further validation. The MTHFR C677T TT genotype was closely associated with elevated HCY levels and a tendency toward a more adverse metabolic phenotype in patients with PMOS. The metabolic implications of this genotype-associated HCY elevation remain exploratory and require confirmation in prospective, multicenter studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.